Real-world practice of the Egyptian Kelleni's protocol amid changing tropism of SARS-CoV-2 omicron BA.5.2.1.7, XBB 1.5 and CH.1.1 subvariants: a multi-purpose protocol.
Mina T KelleniPublished in: Inflammopharmacology (2023)
The Egyptian immune-modulatory Kelleni's protocol, including nitazoxanide as an integral component, is being safely and effectively practiced to manage SARS-CoV-2, RSV, influenza infections in pediatric, adult and pregnant patients with negligible requirements for the relatively expensive diagnostic molecular tests. Most recently, Kelleni's protocol is being likewise used to manage potential norovirus infection which is currently confused with SARS-CoV-2 Omicron new enterotropic subvariants and the antihistaminic loratadine has been co-administered in selected patients. Notably, Africa has the least mandates, restrictions and SARS-CoV-2 vaccination rates and yet the least COVID-19 mortality.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- randomized controlled trial
- end stage renal disease
- healthcare
- ejection fraction
- chronic kidney disease
- newly diagnosed
- primary care
- pregnant women
- coronavirus disease
- prognostic factors
- climate change
- coronary artery disease
- cardiovascular events
- cardiovascular disease
- single molecule
- risk assessment
- ionic liquid
- respiratory tract